Cargando…

A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study

BACKGROUND: The purpose of this study was to evaluate the safety and effectiveness of iloperidone for the prevention of relapse in schizophrenia. METHODS: Study subjects were adults with schizophrenia who started on oral open-label iloperidone titrated to an initial target dose of 12 mg/day (6 mg tw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weiden, Peter J., Manning, Raymond, Wolfgang, Curt D., Ryan, J. Michael, Mancione, Linda, Han, Guangyang, Ahmed, Saeed, Mayo, Mallery G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982888/ https://www.ncbi.nlm.nih.gov/pubmed/27379654 http://dx.doi.org/10.1007/s40263-016-0345-4

Ejemplares similares

New atypical antipsychotics for schizophrenia: iloperidone
por: Caccia, Silvio, et al.
Publicado: (2010)

Reprieve for Perchlorate
por: Renner, R
Publicado: (2002)

Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy
por: Tonin, Fernanda S, et al.
Publicado: (2016)

Ventricular premature contractions associated with iloperidone
por: Achalia, Rashmin, et al.
Publicado: (2013)

Long-term efficacy and safety of iloperidone: an update
por: Rado, Jeffrey T, et al.
Publicado: (2014)

No Reprieve: Extreme Heat at Night Contributes to Heat Wave Mortality
por: Seltenrich, Nate
Publicado: (2023)

Iloperidone-induced Galactorrhea in a Middle-aged Female
por: Dutta, Arghya, et al.
Publicado: (2012)

Iloperidone-induced ejaculatory dysfunction: A case series
por: Ravani, Niraj Narendra, et al.
Publicado: (2016)

Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia
por: Thériault, Rachel-Karson, et al.
Publicado: (2021)

Post-Myocardial Infarction Ventricular Septal Defect: No Reprieve From Doom?
por: Russo, Giulio, et al.
Publicado: (2022)

The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trial
por: Fulda, Evelynne S., et al.
Publicado: (2023)

A Reprieve from US wildlife mortality on roads during the COVID-19 pandemic
por: Shilling, Fraser, et al.
Publicado: (2021)

Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial
por: Douglas, Pamela S, et al.
Publicado: (2021)

A case of iloperidone overdose in a 27-year-old man with cocaine abuse
por: Amon, Jin, et al.
Publicado: (2016)

Synthesis and Characterization of Carbon-11 Labeled Iloperidone for Imaging of α(1)-Adrenoceptor in Brain
por: Xu, Yulong, et al.
Publicado: (2020)

Everybody's Page: How to Live to One Hundred.—A Word on Exercise.—A Welcome Reprieve, etc.
Publicado: (1888)

Sextech Use as a Potential Mental Health Reprieve: The Role of Anxiety, Depression, and Loneliness in Seeking Sex Online
por: Marcotte, Alexandra S., et al.
Publicado: (2021)

The Effect of Chronic Iloperidone Treatment on Cytochrome P450 Expression and Activity in the Rat Liver: Involvement of Neuroendocrine Mechanisms
por: Danek, Przemysław J., et al.
Publicado: (2021)

Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine
por: Boyda, Heidi N., et al.
Publicado: (2013)

The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions
por: Danek, Przemysław J., et al.
Publicado: (2020)

Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus
por: Kileel, Emma M, et al.
Publicado: (2021)

S56. PHOENIX GROUP, A PROJECT TO PREVENT RELAPSES IN SCHIZOPHRENIA
por: Chiramberro, Marcelo, et al.
Publicado: (2018)

Long-Term Treatment with Atypical Antipsychotic Iloperidone Modulates Cytochrome P450 2D (CYP2D) Expression and Activity in the Liver and Brain via Different Mechanisms
por: Danek, Przemysław J., et al.
Publicado: (2021)

The nature of relapse in schizophrenia
por: Emsley, Robin, et al.
Publicado: (2013)

PM431. Effects of iloperidon and nemonaprid on depression, anxiety-like behaviour and locomotion: Altered gen expression levels of FGF2, synapsin and NGF in the hippocampus of mice
por: Mutlu, Oguz, et al.
Publicado: (2016)

The cost of relapse and the predictors of relapse in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2010)

Anomaly detection to predict relapse risk in schizophrenia
por: Henson, Philip, et al.
Publicado: (2021)

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2022)

PHYSICAL HARBINGERS OF RELAPSE IN SCHIZOPHRENIA
por: Srinivasan, T.N., et al.
Publicado: (1994)

Polypharmacy and relapse of schizophrenia: are they related?
por: Softic, R., et al.
Publicado: (2022)

COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Cross, Anne H., et al.
Publicado: (2022)

Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Cross, Anne H., et al.
Publicado: (2022)

O9.7. TECHNOLOGY ASSISTED RELAPSE PREVENTION PROGRAM REDUCES HOSPITALIZATION IN SCHIZOPHRENIA PATIENTS AT HIGH RISK FOR RELAPSE
por: Schooler, Nina, et al.
Publicado: (2020)

The Information Technology Aided Relapse Prevention Programme in Schizophrenia: an extension of a mirror-design follow-up
por: Španiel, F, et al.
Publicado: (2008)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
por: Zhao, Yueren, et al.
Publicado: (2013)

Tailored intervention to prevent relapses and hospitalization in a migrant suffering from paranoid schizophrenia
por: Duvivier, Hélène, et al.
Publicado: (2021)

Quality of life is predictive of relapse in schizophrenia
por: Boyer, Laurent, et al.
Publicado: (2013)

A Patient With Schizophrenia in Remission Relapses Following COVID-19: A Case Report
por: Shaaban, Saeed S, et al.
Publicado: (2022)

STUDY OF RELAPSES IN SCHIZOPHRENIA USING THE LIFE TABLE METHOD
por: Thara, R., et al.
Publicado: (1987)

Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA
por: Aigbogun, Myrlene S, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hlaos5v7piqnprr4nds032fhu9